J.-F. Blanc

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

Valérie Boige, O. Bouché, J.-F. Blanc et al. · British Journal of Cancer · 2007 · 89 citations · Full text

Medicine, Oncology, Pharmacology +15

Investigation of liver fibrosis in clinical practice

J.-F. Blanc, Paulette Bioulac‐Sage, Charles Balabaud et al. · Hepatology Research · 2005 · 38 citations

Medicine, Cell Biology, Pathology +17

Self‐Healing Generalized Infantile Myofibromatosis with Elevated Urinary bFGF

C. Léauté‐Labrèze, M P Labarthe, J.-F. Blanc et al. · Pediatric Dermatology · 2001 · 28 citations

Medicine, Pathobiology, Pathology +5

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng et al. · Annals of Oncology · 2018 · 27 citations · Full text

Medicine, Oncology, Cancer Pharmacology +14

Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study

Andrew X. Zhu, Baek‐Yeol Ryoo, Chung‐Jen Yen et al. · Annals of Oncology · 2014 · 24 citations · Full text

Medicine, Oncology, Pharmacology +11